PTO/SB/08A (07-05)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Mute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

	Complete if Known	
Application Number	10/644,548	
Filing Date	August 20, 2003	
First Named Inventor	Vivien Chan	
Art Unit	1646	
Examiner Name	Eileen B. O'Hara	
Attorney Docket Number	59516-159	

			U.S. PATENT	DOCUMENTS	
Examiner Initials *	Cite No.'	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
EAU	ļ	Number - Kind Code ² (if known)	Figures Appear		
EOH					
	L		07-15-1997	Arvanis-Tsakonas	
V		US- 5,869,037	02-09-1999	Crystal	
		US-			·
-		US-			
		US-			
		US-			
		US-			
•		US-	****		
		US-			
		US-		<u> </u>	
		US-			
		US-	***************************************		

		FOREIGN PA	TENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document	D. Minarian	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T [®]
EOH		WO 98/45434	10-15-1998	WIPO		
J		WO 98/51799	11-19-1998	WIPO		
V		JP 11-299493	11-02-1999	Japan		
	*					
					·	

Examiner /Eileen O'Hara/	Date Considered	01/09/2007
--------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Better Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	e for form 144	9B/PTO			Complete if Known
		AN DIA	01 001105	Application Number	10/644,548
		-	CLOSURE	Filing Date	August 20, 2003
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	Vivien Chan
				Art Unit	1646
	(Use as ma	ny sheets as	necessary)	Examiner Name	Eileen B. O'Hara
Sheet	2	of	4	Attorney Docket Number	59516-159

	· · · · · · · · ·	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	man 1 1 1 1 min man (a a and madamina) la minad a a man a la minada a man a la man a la man a la man a la man a		T²
ЕОН		TONON et al., t(11:19)(q21:p13) Translocation in Mucoepidermoid Carcinoma Creates a Novel Fusion Product That Disrupts a Notch Signaling Pathway, Nat. Genet., 33:208-213; 2003.	
		AITKENHEAD et al., Identification of Endothelial Cell Genes Expressed in an In Vitro Model of Angiogenesis: Induction of ESM-1, Big-h3, and NrCAM, <i>Microvascular Res.</i> , 63:159-171, 2002.	
		LEONG et al., Activitated Notch-4 Inhibits Angiogenesis: Role of ß1-Integrin Activation, Mol. Cell. Biol., 22:2830-2841, 2002.	
		CALLAHAN et al., Notch Signaling in Mammary Gland Tumorigenesis, J. Mammary Gland Biol. Neoplasia, 6:23-36, 2001.	
		Genbank Accession No. AL078605, April 29, 2000.	l
		RADTKE et al., Deficient T Cell Fate Specification in Mice With an Induced Inactivation of Notch1, Immunity 10(5):547-558, May 1999.	
		XUE et al., Embryonic Lethality and Vascular Defects in Mice Lacking the Notch Ligand Jagged1, Hum. Mol. Gen. 8(5):723-730, May 1999.	
		ZECCHINI et al., An Activity of Notch Regulates JNK Signalling and Affects Dorsal Closure in <i>Drosophila</i> , <i>Current Biology</i> 9(9):460-469, April 21, 1999.	
		Abstract of JP11299493, esp@cenet database, November 2, 1999.	
_		Accession No. Y11895, March 14, 1997.	
\		Derwent dgene database, Accession No. AAX16303, April 22, 1999.	

Examiner Date 01/09/3	2007
---------------------------	------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

S	Substitute	for form 1449	В/РТО			Complete if Known	
			a a.	201 001105	Application Number	10/644,548	
				SCLOSURE	Filing Date	August 20, 2003	
5	STAT	EMEN.	L BA V	PPLICANT	First Named Inventor	Vivien Chan	
					Art Unit	1646	
		(Use as mai	ny sheets a	s necessary)	Examiner Name	Eileen B. O'Hara	
S	Sheet	3	of	4	Attorney Docket Number	59516-159	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
EOH		GRAY et al., Human Ligands of the Notch Receptor, Am J Pathol. 154(3):785-794, March 1999.	
		LENDAHL, A Growing Family of Notch Ligands, BioEssays 20(2):103-107, February 1998.	
	 	SALLOWAY et al., CADASIL Syndrome: A Genetic Form of Vascular Dementia, J. Geriatr. Psychiatry Neurol. 11(2):71-77, Summer 1998.	
		Genbank Accession No. AB013440, October 9, 1998.	
		BOULTER et al., DatabaseGenEmbl, Accession No. AF084576, August 30, 1998.	
		Database EST, Accession No. Al089793, October 1, 1998.	
		DUNWOODIE et al., Mouse D113: A Novel Divergent Delta Gene Which May Complement the Function of Other Delta Homologues During Early Pattern Formation in the Mouse Embryo, <i>Development 124</i> (16):3065-3076, August 1997.	
		JOUTEL et al., Strong Clustering and Stereotyped Nature of Notch3 Mutations in CADASIL Patients, Lancet 350(9090):1511-1515, November 22, 1997.	
		LI et al., Alagille Syndrome is Caused by Mutations in Human Jagged1, Which Encodes a Ligand for Notch1, Nature Genetics 16(3):243-251, July 1997.	
		MAGOVERN et al., Regional Angiogenesis Induced in Nonischemic Tissue by an Adenoviral Vector Expressing Vascular Endothelial Growth Factor, <i>Human Gene Therapy 8</i> :215-227, January 20, 1997.	
$\overline{\Psi}$		ODA et al., Mutations in the Human Jagged1 Gene are Responsible for Alagille Syndrome, Nature Genetics 16(3):235-242, July 1997.	

Examiner	/Eileen O'Hara/	Date	01/00/2007
Signature	/Bileen O nara/	Considered	01/09/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through chaudin in form conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449B/PT	О		Complete if Known				
INIEO		. DIC	OL COURT	Application Number	10/644,548			
			CLOSURE	Filing Date	August 20, 2003			
STAT	LEMENT B	BY A	PPLICANT	First Named Inventor	Vivien Chan			
				Art Unit	1646			
	(Use as many sh	eets as	necessary)	Examiner Name	Eileen B. O'Hara			
Sheet	4	of	4	Attorney Docket Number	59516-159			

		NON PATENT LITERATURE DOCUMENTS	
Examin Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ЕОН		SHIRAYOSHI, Proto-Oncogene of INT-3, A Mouse Notch Homologue, Is Expressed in Endothelial Cells During Early Embryogenesis, <i>Genes to Cells</i> 2(3):213-224, March 1997.	
		UYTTENDAELE, Notch4/int-3, A Mammary Proto-Oncogene, Is an Endothelial Cell-Specific Mammalian Notch Gene, Development 122(7):2251-2259, July 1996.	
		ZIMRIN et al., An Antisense Oligonucleotide to the Notch Ligand Jagged Enhances Fibroblast Growth Factor-Induced Angiogenesis in Vitro, <i>Jour. Biol. Chem.</i> 271(51):32499-32502, December 20, 1996.	
		FITZGERALD et al., Interchangeability of Caenorhabditis Elegans DSL Proteins and Intrinsic Signalling Activity of Their Extracellular Domains in Vivo, <i>Development 121</i> (12):4275-4282, December 1995.	
		Genbank Accession No. Z48825, March 30, 1995.	
		ELLISEN et al., TAN-1, The Human Homolog of the Drosophila Notch Gene, Is Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms, <i>Cell</i> 66(4):649-661, August 23, 1991.	
V		MONTESANO et al., Tumor-Promoting Phorbol Esters Induce Angiogenesis in Vitro, Cell 42(2):469-477, September 1985.	
			
······································			

Examiner		Date	01/00/0007
Signature	/Eileen O'Hara/	Considered	01/09/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.